All public logs

From Beacon

Combined display of all available logs of Beacon. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

Logs
(newest | oldest) View ( | ) (20 | 50 | 100 | 250 | 500)
  • 00:32, 30 November 2023 Woloski talk contribs created page Uppsala University Hospital Trials (Created page with "'''NCTID''': NCT00036556 '''Title''': Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer '''Study Summary''': This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer. '''Sponsor''': Abbott '''Intervention''': Atrasentan '''Start Date''': 2001-06 '''Last Updated''': 2007-08-15 '''Number of Patients''': 941 '''Recruitment Status''': COMPLETED '...")
  • 00:30, 30 November 2023 Woloski talk contribs created page Sahlgrenska University Hospital Trials (Created page with "'''NCTID''': NCT03685890 '''Title''': Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion '''Study Summary''': To evaluate safety and the effect of isolated limb perfusion together with nivolumab as a way to increase efficacy and give further insights in early immunological mechanisms. In the first phase Ib part, 20 patients will be enrolled and followed for a minimum of 3 months. An independent data safety...")
  • 00:26, 30 November 2023 Woloski talk contribs created page Skåne University Hospital Cancer Centre Trials (Created page with "'''NCTID''': NCT02730416 '''Title''': Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer '''Study Summary''': This study will evaluate the role of addition of an anti-angiogenic agent (Nintedanib/placebo) to conventional combination chemotherapy as concomitant and maintenance treatment in primary advanced or with first relapse of endometrial cancer. '''Sponsor''': Nordic Society of Gynaecological Oncology - Clinical Trials Unit '''Interventi...")
  • 00:23, 30 November 2023 Woloski talk contribs created page Karolinska Institute and University Hospital Trials (Created page with "'''NCTID''': NCT01360554 '''Title''': ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer '''Study Summary''': This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of pr...")
  • 00:14, 30 November 2023 Woloski talk contribs created page Catalan Institute of Oncology Trials (Created page with "'''NCTID''': NCT02831959 '''Title''': Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). '''Study Summary''': The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 inoperable brain metastasis or 2-10 brain...")
  • 00:08, 30 November 2023 Woloski talk contribs created page Vall d’Hebron Barcelona Hospital Campus Trials (Created page with "'''NCTID''': NCT00036556 '''Title''': Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer '''Study Summary''': This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer. '''Sponsor''': Abbott '''Intervention''': Atrasentan '''Start Date''': 2001-06 '''Last Updated''': 2007-08-15 '''Number of Patients''': 941 '''Recruitment Status''': COMPLETED '...")
  • 00:00, 30 November 2023 Woloski talk contribs created page Fundación Instituto Valenciano de Oncología IVO Trials (Created page with "'''NCTID''': NCT05947903 '''Title''': Validation of the European Oncology Quality of Life Toolkit '''Study Summary''': The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PR...")
  • 23:34, 29 November 2023 Woloski talk contribs created page Institute of Oncology Ljubljana Trials (Created page with "'''NCTID''': NCT06060990 '''Title''': Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract Cancers '''Study Summary''': The aim of the study is to determine the total concentration of selected trace elements (Cu, Zn, Fe), the proportion of free Cu and Cu bound to ceruloplasmin and the isotopic ratio of Cu65/Cu63 in blood serum samples from healthy volunteers and cancer patients using inductively coupled plasma mass spectr...")
  • 17:59, 29 November 2023 Larysse talk contribs created page Data Dictionary: The Medicines Statistics Register (NPR) (Created page with "Go back to Denmark page Source: [https://www.esundhed.dk/Dokumentation?rid=14&tid=63&vid=317] {| class="wikitable" ! Variables !! Field description |- | aref || Reimbursement schemes that cannot be fitted under the other fields (for shipments from pharmacies where other subsidies have been paid) |- | abc || code for the price of the drug relative to the others in the substitution group |- | aip || The pharmacy's purchase price for one pack at the time of valuation...")
  • 13:51, 29 November 2023 Francine talk contribs created page Data Dictionary - National Registry of Childhood Cancer (RNCCR) (Created page with "=== Variables: === *CNP *Name *First name *Date of birth *Age *Sex *County *City *Address *Date of cancer diagnosis *Explication (reason for registering the diagnosis: hospitalization, death, biopsy, etc.) *Date of clinical onset *Date of relapse *Reason for reporting *Registration base (data source) *Tumor location *Topographical code *Laterality '''Histopathological/cytological examination:''' *Behavior *Morphological code *Degree *Cod ICC3 primary *Cod ICC3...")
  • 13:43, 29 November 2023 Francine talk contribs created page Available Data Dictionary - National Registry of Childhood Cancer (RNCCR) (Created page with "=== Available Variables: === *CNP *Name *First name *Date of birth *Age *Sex *County *City *Address *Date of cancer diagnosis *Explication (reason for registering the diagnosis: hospitalization, death, biopsy, etc.) *Date of clinical onset *Date of relapse *Reason for reporting *Registration base (data source) *Tumor location *Topographical code *Laterality '''Histopathological/cytological examination:''' *Behavior *Morphological code *Degree *Cod ICC3 primary *...")
  • 02:26, 29 November 2023 Woloski talk contribs created page Instituto Português de Oncologia de Coimbra Francisco Gentil Trials (Created page with "'''NCTID''': NCT04459715 '''Title''': A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) '''Study Summary''': The primary objective of the study is to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradio...")
  • 02:24, 29 November 2023 Woloski talk contribs created page Instituto Português de Oncologia de Lisboa Francisco Gentil Trials (Created page with "'''NCTID''': NCT04410445 '''Title''': Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence '''Study Summary''': The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence....")
  • 02:19, 29 November 2023 Woloski talk contribs created page Instituto Português de Oncologia do Porto Francisco Gentil Trials (Created page with "'''NCTID''': NCT02500043 '''Title''': Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer '''Study Summary''': The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer. '''Sponsor''': Taiho Oncology, Inc. '''Intervention''': TAS-102 '''Start Date''': 2016-02-24 '''Last Updated''': 2021-09-16 '''Number of Pati...")
  • 02:17, 29 November 2023 Woloski talk contribs created page Greater Poland Cancer Centre Trials (Created page with "'''NCTID''': NCT02467907 '''Title''': Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer '''Study Summary''': This study is to assess safety as defined by the frequency and severity of gastrointestinal (GI) perforation/fistula, GI-vaginal fistula and genitourinary (GU) fistula in participants treated with bevacizumab 15 milligrams per kilogram (mg/kg) in combination with paclitaxel...")
  • 02:07, 29 November 2023 Woloski talk contribs created page Maria Sklodowska- Curie National Research Institute of Oncology Trials (Created page with "'''NCTID''': NCT03517137 '''Title''': Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study '''Study Summary''': The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET/CT results in improved efficacy while minimizing treatment toxicity in advanced stage Hodgkin Lymphoma (HL) patients treated with brentuximab vedotin (BV)-containing regimens. '''Sponsor''': Europ...")
  • 02:03, 29 November 2023 Woloski talk contribs created page The “Prof. Dr. Ion Chiricuta” Institute of Oncology Trials (Created page with "'''NCTID''': NCT06112314 '''Title''': IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) '''Study Summary''': This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma. '''Sponsor''': Immunocore Ltd '''Intervention''': IMC-F106C '''Start Date''': 2023-12-01 '''Last Updated...")
  • 01:59, 29 November 2023 Woloski talk contribs created page National Cancer Institute Trials (Created page with "'''NCTID''': NCT03425643 '''Title''': Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) '''Study Summary''': This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery <math di...")
  • 01:52, 29 November 2023 Woloski talk contribs created page Riga Eastern Clinical University Hospital Trials (Created page with "'''NCTID''': NCT01903733 '''Title''': Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 '''Study Summary''': The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint. '...")
  • 01:48, 29 November 2023 Woloski talk contribs created page Saolta University Cancer Network Galway University Hospitals Trials (Created page with "'''NCTID''': NCT01176487 '''Title''': Palliative 3-Dimensional Conformal Radiation Therapy in Reducing Radiation Side Effects in Patients With Lung Cancer. ICORG 06-34 '''Study Summary''': RATIONALE: 3-dimensional conformal radiation therapy may lessen side effects caused by palliative radiation therapy and improve the quality of life of patients with lung cancer. PURPOSE: This clinical trial is studying how well 3-dimensional conformal radiation therapy works in re...")
  • 01:37, 29 November 2023 Woloski talk contribs created page Trinity St. James’s Cancer Institute Trials (Created page with "'''NCTID''': NCT05947903 '''Title''': Validation of the European Oncology Quality of Life Toolkit '''Study Summary''': The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PR...")
  • 01:30, 29 November 2023 Woloski talk contribs created page National Institute of Oncology Trials (Created page with "'''NCTID''': NCT05169567 '''Title''': Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer '''Study Summary''': This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibito...")
  • 01:24, 29 November 2023 Woloski talk contribs created page University Cancer Center Frankfurt Trials (Created page with "'''NCTID''': NCT04821622 '''Title''': Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC '''Study Summary''': The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC. '''Sponsor''': Pfizer '''Intervention''': talazoparib plus enzalutamide '''Start Date''': 2021-05-12 '''Last Updated''':...")
  • 01:12, 29 November 2023 Woloski talk contribs created page Charité Comprehensive Cancer Center Trials (Created page with "'''NCTID''': NCT02951767 '''Title''': A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) '''Study Summary''': This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts. Cohort 1 (reported here) will consist of participants who are treatment-naï...")
  • 01:07, 29 November 2023 Woloski talk contribs created page National Cancer Center Dresden Trials (Created page with "'''NCTID''': NCT03430843 '''Title''': A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma '''Study Summary''': The purpose of this study is to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that has progressed during or after first line therapy. '''Sponsor''': BeiGene '''Intervention''':...")
  • 18:36, 28 November 2023 Woloski talk contribs created page Institut Sainte Catherine Trials (Created page with "'''NCTID''': NCT01300143 '''Title''': Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma '''Study Summary''': Indication : Hepatocellular carcinoma, maximum size 9 cm, with single or multiple nodes whose total tumor mass can technically be irradiated, non-resectable, and not a candidate for percutaneous therapy with recommended treatment via hyperselective transarteri...")
  • 18:32, 28 November 2023 Woloski talk contribs created page Centre Henri Becquerel Trials (Created page with "'''NCTID''': NCT04712097 '''Title''': A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma '''Study Summary''': This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination wi...")
  • 18:29, 28 November 2023 Francine talk contribs created page Data Dictionary: National Cancer Registry (Created page with "{| class="wikitable" |+ Data Dictionary |- | Address 1 |- | Address 2 |- | Address 3 |- | Address 4 |- | Address 5 |- | Address Id |- | Admission Type |- | Age At Incidence |- | Also Known As |- | Approximate Treatment Date |- | Care of Address |- | Clinical M |- | Clinical N |- | Clinical T |- | Clinical Tumour Size |- | Closed Date |- | Comment Date |- | Comment Id |- | Consultant |- | County Id |- | Date of Birth |- | Date of Death |- | Date of Incidence |- | Date of...")
  • 18:25, 28 November 2023 Woloski talk contribs created page Georges-François Leclerc Cancer Center Trials (Created page with "'''NCTID''': NCT02947685 '''Title''': Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer '''Study Summary''': The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast can...")
  • 18:21, 28 November 2023 Woloski talk contribs created page Institut Godinot Trials (Created page with "'''NCTID''': NCT03943667 '''Title''': Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma '''Study Summary''': This study aims to evaluate whether the combination of gemcitabine and paclitaxel allows to improve the overall survival compared to gemcitabine alone, in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) after FOLFIRINOX failure or intolerance. '''Sponsor''': UNICANCER ''...")
  • 18:17, 28 November 2023 Francine talk contribs created page Data Dictionary: Compilation: Department of Health Databases (CSO) (Created page with "{| class="wikitable" |+ Data on discharge, diagnostics, and procedures for inpatients |- | Age-Standardised Data for Principal Procedure |- | Age-Standardised Morbidity Rate for Principal Procedures |- | In-Patient and Daycase Principal Procedures and Average Length of Hospital Stay |- | Hospital Discharges of In-Patients, Daycases and Length of Stay (All Procedures) |- | Hospital Discharges of In-Patients, Daycases and Length of Stay (National Data - All Procedures) |-...")
  • 18:13, 28 November 2023 Woloski talk contribs created page Institut du Cancer de Montpellier Trials (Created page with "'''NCTID''': NCT00875667 '''Title''': A Study to Determine the Efficacy of Lenalidomide Versus Investigator’s Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) '''Study Summary''': To evaluate the safety and efficacy of lenalidomide versus investigator choice in patients with relapsed or refractory mantle cell lymphoma. '''Sponsor''': Celgene '''Intervention''': Lenalidomide '''Start Date''': 2009-04-30 '''Last Updated''': 2019-09-16...")
  • 18:09, 28 November 2023 Woloski talk contribs created page Comprehensive Cancer Center Jean Perrin Trials (Created page with "'''NCTID''': NCT01491737 '''Title''': A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer '''Study Summary''': This randomized, open-label, two-arm, multi-center, Phase II study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab plus an aromatase inhibitor (AI) in f...")
  • 18:03, 28 November 2023 Woloski talk contribs created page Cancer Institute Strasbourg Europe Trials (Created page with "'''NCTID''': NCT04717414 '''Title''': An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions '''Study Summary''': The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF...")
  • 17:55, 28 November 2023 Woloski talk contribs created page Gustave Roussy Trials (Created page with "'''NCTID''': NCT02666690 '''Title''': Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast '''Study Summary''': RECIST criteria for evaluating tumor response are often inadequate for the evaluation of anti-angiogenic drugs. An evaluation model of tumor perfusion with contrast-enhanced ultrasonography was developed at Gustave Roussy. It assesses the tumor vascular response through the analysis of 7...")
  • 17:52, 28 November 2023 Woloski talk contribs created page Eugène Marquis Cancer Centre Trials (Created page with "'''NCTID''': NCT02444000 '''Title''': gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas '''Study Summary''': Patients with 1p/19q-codeleted anaplastic gliomas treated with RT + PCV are at risk of neurocognitive deterioration. Treating these patients with PCV alone (could reduce the risk of neurocognitive deterioration without impairing overall survival. '''Sponsor''': Assistance Publique - Hôpitaux de Paris '''Intervention''': PCV chemotherapy alone '''St...")
  • 17:48, 28 November 2023 Woloski talk contribs created page Institut de Cancérologie de l'Ouest (ICO) - Integrated Center for Oncology Trials (Created page with "'''NCTID''': NCT03943667 '''Title''': Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma '''Study Summary''': This study aims to evaluate whether the combination of gemcitabine and paclitaxel allows to improve the overall survival compared to gemcitabine alone, in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) after FOLFIRINOX failure or intolerance. '''Sponsor''': UNICANCER ''...")
  • 17:44, 28 November 2023 Woloski talk contribs created page APHP - Sorbonne Université - Institut Universitaire de Cancérologie(IUC) Trials (Created page with "'''NCTID''': NCT04622319 '''Title''': A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) '''Study Summary''': Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options ar...")
  • 17:10, 28 November 2023 Francine talk contribs created page Cancer Areas of Interest: I.Stat - Smoking Habits (Created page with "{| class="wikitable" |+ Cancers and Diagnoses ! ICD-10 Code !! Diagnoses |- | C00-C14 || Cancers of the oral cavity and pharynx |- | C15 || Cancer of the esophagus |- | C16 || Cancer of the stomach |- | C18-C21 || Cancers of the colon and rectum |- | C22 || Cancer of the liver |- | C25 || Cancer of the pancreas |- | C32 || Cancer of the larynx |- | C33-C34 || Cancers of the lung, bronchus, and trachea |- | C64-C65 || Cancers of the kidney and renal pelvis |- | C67 || Can...")
  • 17:08, 28 November 2023 Woloski talk contribs created page Centre François Baclesse Trials (Created page with "'''NCTID''': NCT01827943 '''Title''': Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer '''Study Summary''': In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival. '''Sponsor''': Institut Bergonié '''Intervention''': Temsirolimus '''Start Date''': 2009-06 '''Last Updated''...")
  • 16:59, 28 November 2023 Francine talk contribs created page Cancer Areas of Interest: I.Stat - Causes of Death (Created page with "{| class="wikitable" |+ Malignant Neoplasms and Diagnoses ! ICD-10 Code !! Diagnoses |- | C00-C14 || Malignant neoplasm of lip, oral cavity, and pharynx |- | C15 || Malignant neoplasm of esophagus |- | C16 || Malignant neoplasm of stomach |- | C18-C21 || Malignant neoplasm of colon, rectum, and anus |- | C22 || Malignant neoplasm of liver |- | C25 || Malignant neoplasm of pancreas |- | C32 || Malignant neoplasm of larynx |- | C33-C34 || Malignant neoplasm of trachea, bro...")
  • 16:42, 28 November 2023 Woloski talk contribs created page University Cancer Institute Toulouse-Oncopole Trials (Created page with "'''NCTID''': NCT06112314 '''Title''': IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) '''Study Summary''': This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma. '''Sponsor''': Immunocore Ltd '''Intervention''': IMC-F106C '''Start Date''': 2023-12-01 '''Last Updated...")
  • 15:52, 28 November 2023 Woloski talk contribs created page Institut Paoli-Calmettes Trials (Created page with "'''NCTID''': NCT04070443 '''Title''': Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase '''Study Summary''': The investigators hypothesize that, in newly diagnosed de novo chronic phase CML patients, an induction treatment with ponatinib for 6 months should increase the rate of patients reaching a stable MR4.5 allowing cessation of imatinib treatment. The investigators proposal is to conduct a multicen...")
  • 01:23, 28 November 2023 Woloski talk contribs created page Institut Curie Trials (Created page with "'''NCTID''': NCT03875573 '''Title''': Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: '''Study Summary''': Neo-CheckRay is a multicenter, open-label phase II study that randomizes luminal B breast cancer subjects candidate for neo-adjuvant chemotherapy in a 1:1:1 ratio in 3 arms: 1. the combination of weekly paclitaxel followed by dose-dense doxorubicin-cyclophospham...")
  • 01:16, 28 November 2023 Woloski talk contribs created page Léon Bérard Center Trials (Created page with "'''NCTID''': NCT03525392 '''Title''': Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. '''Study Summary''': This study was being conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1). This study was a first administration of a radioactive drug called 177Lu-3BP-227 to patients under cont...")
  • 00:42, 28 November 2023 Woloski talk contribs created page File:Latvia female.png
  • 00:42, 28 November 2023 Woloski talk contribs uploaded File:Latvia female.png
  • 00:38, 28 November 2023 Woloski talk contribs created page File:Latvia all.png
  • 00:38, 28 November 2023 Woloski talk contribs uploaded File:Latvia all.png
  • 22:31, 27 November 2023 Woloski talk contribs created page Oulu University Hospital Trials (Created page with "'''NCTID''': NCT04607421 '''Title''': A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer '''Study Summary''': The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: * has spread to other parts of the body (metastatic); * has a certain type of abnorma...")
(newest | oldest) View ( | ) (20 | 50 | 100 | 250 | 500)
Retrieved from "https://wiki.beaconcancer.org/index.php?title=Special:Log"
Powered by MediaWiki
Powered by Semantic MediaWiki